Istanbul-based Eczacibasi-Monrol Nuclear Products (Monrol) said it plans to open a facility in Germany to produce radiopharmaceuticals for imaging and radioligand therapy.
The manufacturing facility will be focused on producing gallium-68 and non-carrier-added lutetium-177, radiopharmaceuticals that are used to image and treat cancer, such as prostate cancer and neuroendocrine tumors, the company said.
The new facility is scheduled to be up and running by 2026 at an estimated cost of about 30 million euros.
